(ONC-DPX-Survivac-06): A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac with Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients with Recurrent Ovarian Cancer

Principal Investigator

Tanja Pejovic

Study Purpose

Phase 2 of this clinical trial evaluates the safety and effectiveness of an investigational cancer vaccine, DPX-Survivac, plus low-dose oral cyclophosphamide in women with proven recurrent ovarian cancer.

Medical Condition(s)

Ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer

Eligibility Criteria

1. Confirmed diagnosis of Stage IIc-IV epithelial ovarian, fallopian tube, or peritoneal cancer and completion of first-line treatment.

2. Evidence of progressive disease-- either by rising CA-125 and/or radiologic imaging-- at least 3 months after completion of first-line platinum-based chemotherapy (other therapies after first-line are allowed).

3. Must be willing to have a pre-treatment tumor biopsy performed, and be willing to undergo tumor biopsy during treatment as well.

4. Other criteria will apply

Age Range

18 - 99

Healthy Volunteers Needed


Duration of Participation

Participation can continue for one year, or until subjects experience disease progression or develop intolerable side effects, whichever occurs first. After participation ends, subjects will be followed every 6 months for 5 years.

Minors Included



Yukie Tarumi Bean, CCRP
Gyn/Onc Study Coordinator


ImmunoVaccine Technologies Inc. (IMV, Inc.)

Recruitment End


Compensation Provided


Go Back